Literature DB >> 1959381

Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes.

P Druzgala1, W M Wu, N Bodor.   

Abstract

Loteprednol etabonate (LE) is a "soft" steroid belonging to a unique class of glucocorticoids. LE possesses a metabolically labile 17 beta-chloromethyl ester function which was designed in order to be hydrolyzed to an inactive carboxylic acid moiety. The ocular absorption and metabolism of a 14C-labelled LE was evaluated in New-Zealand White rabbits after administration of a 0.5% suspension in both eyes. At various time points following ocular administration, the cornea, aqueous humor, and iris-ciliary body were collected. LE and the putative inactive metabolites, PJ-90 and PJ-91, were identified in all 3 tissues. Levels of LE and its metabolites were highest in the cornea, and so was the ratio of metabolites to unchanged drug, suggesting that the primary site of deactivation of the drug is the corneal tissue. A substantial amount of metabolites were also detected in the iris-ciliary body, although to a lesser extent than in the cornea. The amount of drug and metabolites in the aqueous humor was very low. It is concluded that LE is indeed a soft steroid with good ocular permeation properties.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1959381     DOI: 10.3109/02713689109020329

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  21 in total

Review 1.  Locally administered ocular corticosteroids: benefits and risks.

Authors:  Charles N J McGhee; Simon Dean; Helen Danesh-Meyer
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 2.  Corticosteroids and glaucoma risk.

Authors:  R C Tripathi; S K Parapuram; B J Tripathi; Y Zhong; K V Chalam
Journal:  Drugs Aging       Date:  1999-12       Impact factor: 3.923

3.  Topical loteprednol etabonate 0.5 % for treatment of vernal keratoconjunctivitis: efficacy and safety.

Authors:  Veysi Oner; Fatih Mehmet Türkcü; Mehmet Taş; Mehmet Fuat Alakuş; Yalçın Işcan
Journal:  Jpn J Ophthalmol       Date:  2012-05-25       Impact factor: 2.447

4.  Safety and tolerability of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension in pediatric subjects.

Authors:  Timothy L Comstock; Michael R Paterno; Kirk M Bateman; Heleen H Decory; Matthew Gearinger
Journal:  Paediatr Drugs       Date:  2012-04-01       Impact factor: 3.022

Review 5.  Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems.

Authors:  Nicholas Bodor; Peter Buchwald
Journal:  AAPS J       Date:  2005-12-07       Impact factor: 4.009

Review 6.  Advances in the use of prodrugs for drug delivery to the eye.

Authors:  Pranjal Taskar; Akshaya Tatke; Soumyajit Majumdar
Journal:  Expert Opin Drug Deliv       Date:  2016-07-21       Impact factor: 6.648

Review 7.  Ocular itch associated with allergic conjunctivitis: latest evidence and clinical management.

Authors:  Stacey Ackerman; Lisa M Smith; Paulo J Gomes
Journal:  Ther Adv Chronic Dis       Date:  2016-01       Impact factor: 5.091

Review 8.  Synthesis and pharmacology of anti-inflammatory steroidal antedrugs.

Authors:  M Omar F Khan; Henry J Lee
Journal:  Chem Rev       Date:  2008-12       Impact factor: 60.622

9.  Metabolism, distribution, and transdermal permeation of a soft corticosteroid, loteprednol etabonate.

Authors:  N Bodor; T Loftsson; W M Wu
Journal:  Pharm Res       Date:  1992-10       Impact factor: 4.200

Review 10.  Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives.

Authors:  Sherif A Gaballa; Uday B Kompella; Omar Elgarhy; Ali M Alqahtani; Barbara Pierscionek; Raid G Alany; Hamdy Abdelkader
Journal:  Drug Deliv Transl Res       Date:  2021-06       Impact factor: 4.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.